secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000950170-22-024448
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx reports Q3 net loss of $53.8M; FDA-approved RELYVRIO now commercially available in U.S.
--------------------------------------------------------------------------------

- FDA approval of RELYVRIO for ALS on Sep 29; shipments began Oct 24.
- ALBRIOZA launched in Canada Jul 29, generating $0.3M net product revenue in Q3.
- Net loss $53.8M ($0.92/sh) vs $23.1M ($3.42/sh) YoY; R&D and SG&A costs rose on launch preparation.
- Cash $162.6M at Sep 30, plus $230.8M net from October stock offering.
- EMA decision on AMX0035 expected first half 2023; MAA under review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000095017022024448/0000950170-22-024448-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000095017022024448/amlx-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024448

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer